Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study
Background: Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings. We then aimed to evaluate the incidence of thrombo...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Brain Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3425/13/11/1541 |
| _version_ | 1827640398719221760 |
|---|---|
| author | Irene Scala Simone Bellavia Pier Andrea Rizzo Jacopo Di Giovanni Mauro Monforte Roberta Morosetti Giacomo Della Marca Fabio Pilato Aldobrando Broccolini Paolo Profice Giovanni Frisullo |
| author_facet | Irene Scala Simone Bellavia Pier Andrea Rizzo Jacopo Di Giovanni Mauro Monforte Roberta Morosetti Giacomo Della Marca Fabio Pilato Aldobrando Broccolini Paolo Profice Giovanni Frisullo |
| author_sort | Irene Scala |
| collection | DOAJ |
| description | Background: Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings. We then aimed to evaluate the incidence of thromboembolic events and the persistence of edoxaban therapy in the long-term. Methods: In this observational cohort study, we included ischemic stroke patients enrolled in a previous study to evaluate the safety and efficacy of long-term edoxaban treatment. Data were collected by a trained investigator through a structured telephone interview. Results: Sixty-three subjects (median age 81.0 (73.5–88.0) years, 38.1% male) were included in the study, with a mean follow-up of 4.4 ± 0.7 years (range: 3.2–5.5 years). Only one patient (1.6%, 0.4%/year) presented a major extracranial bleeding, and none had cerebral hemorrhage. Six thromboembolic events occurred in five patients (7.9%): three recurrent strokes, two transient ischemic attacks, and one myocardial infarction (2.2%/year). Over a follow-up period of more than three years, 13 patients discontinued edoxaban (20.6%). <b>Conclusions:</b> Edoxaban seems to be effective and safe in the long-term. The persistence rate of edoxaban therapy is optimal after more than three years of treatment. |
| first_indexed | 2024-03-09T16:59:09Z |
| format | Article |
| id | doaj.art-f755b5fc55c94be48afd8ca1cc428261 |
| institution | Directory Open Access Journal |
| issn | 2076-3425 |
| language | English |
| last_indexed | 2024-03-09T16:59:09Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Brain Sciences |
| spelling | doaj.art-f755b5fc55c94be48afd8ca1cc4282612023-11-24T14:32:40ZengMDPI AGBrain Sciences2076-34252023-11-011311154110.3390/brainsci13111541Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES StudyIrene Scala0Simone Bellavia1Pier Andrea Rizzo2Jacopo Di Giovanni3Mauro Monforte4Roberta Morosetti5Giacomo Della Marca6Fabio Pilato7Aldobrando Broccolini8Paolo Profice9Giovanni Frisullo10School of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, ItalySchool of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, ItalySchool of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, ItalySchool of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, ItalyDepartment of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, ItalyDepartment of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, ItalySchool of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, ItalyNeurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Fondazione Campus Bio-Medico di Roma, 00128 Rome, ItalySchool of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, ItalyUOC Neurologia and Stroke Unit, Mater Olbia Hospital, 07026 Olbia, ItalyDepartment of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, ItalyBackground: Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings. We then aimed to evaluate the incidence of thromboembolic events and the persistence of edoxaban therapy in the long-term. Methods: In this observational cohort study, we included ischemic stroke patients enrolled in a previous study to evaluate the safety and efficacy of long-term edoxaban treatment. Data were collected by a trained investigator through a structured telephone interview. Results: Sixty-three subjects (median age 81.0 (73.5–88.0) years, 38.1% male) were included in the study, with a mean follow-up of 4.4 ± 0.7 years (range: 3.2–5.5 years). Only one patient (1.6%, 0.4%/year) presented a major extracranial bleeding, and none had cerebral hemorrhage. Six thromboembolic events occurred in five patients (7.9%): three recurrent strokes, two transient ischemic attacks, and one myocardial infarction (2.2%/year). Over a follow-up period of more than three years, 13 patients discontinued edoxaban (20.6%). <b>Conclusions:</b> Edoxaban seems to be effective and safe in the long-term. The persistence rate of edoxaban therapy is optimal after more than three years of treatment.https://www.mdpi.com/2076-3425/13/11/1541NOACsDOACsedoxabanatrial fibrillationstrokecardioembolism |
| spellingShingle | Irene Scala Simone Bellavia Pier Andrea Rizzo Jacopo Di Giovanni Mauro Monforte Roberta Morosetti Giacomo Della Marca Fabio Pilato Aldobrando Broccolini Paolo Profice Giovanni Frisullo Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study Brain Sciences NOACs DOACs edoxaban atrial fibrillation stroke cardioembolism |
| title | Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study |
| title_full | Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study |
| title_fullStr | Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study |
| title_full_unstemmed | Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study |
| title_short | Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study |
| title_sort | prolonged secondary stroke prevention with edoxaban a long term follow up of the sates study |
| topic | NOACs DOACs edoxaban atrial fibrillation stroke cardioembolism |
| url | https://www.mdpi.com/2076-3425/13/11/1541 |
| work_keys_str_mv | AT irenescala prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT simonebellavia prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT pierandrearizzo prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT jacopodigiovanni prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT mauromonforte prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT robertamorosetti prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT giacomodellamarca prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT fabiopilato prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT aldobrandobroccolini prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT paoloprofice prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy AT giovannifrisullo prolongedsecondarystrokepreventionwithedoxabanalongtermfollowupofthesatesstudy |